Document is current
Any future updates will be listed below
-
Authors
Zost, Seth J. https://orcid.org/0000-0001-6712-5076
Gilchuk, Pavlo
Chen, Rita E.
Case, James Brett
Reidy, Joseph X.
Trivette, Andrew
Nargi, Rachel S.
Sutton, Rachel E.
Suryadevara, Naveenchandra
Chen, Elaine C. https://orcid.org/0000-0001-7883-8039
Binshtein, Elad https://orcid.org/0000-0003-2745-104X
Shrihari, Swathi https://orcid.org/0000-0002-8188-6936
Ostrowski, Mario
Chu, Helen Y.
Didier, Jonathan E.
MacRenaris, Keith W.
Jones, Taylor
Day, Samuel
Myers, Luke https://orcid.org/0000-0003-1132-2550
Eun-Hyung Lee, F. https://orcid.org/0000-0002-6133-5942
Nguyen, Doan C. https://orcid.org/0000-0002-5389-6731
Sanz, Ignacio https://orcid.org/0000-0003-4182-587X
Martinez, David R.
Rothlauf, Paul W.
Bloyet, Louis-Marie
Whelan, Sean P. J. https://orcid.org/0000-0003-1564-8590
Baric, Ralph S.
Thackray, Larissa B. https://orcid.org/0000-0002-9380-6569
Diamond, Michael S.
Carnahan, Robert H. https://orcid.org/0000-0001-5230-1532
Crowe, James E. Jr. https://orcid.org/0000-0002-0049-1079
-
Funding
Funding for this research was provided by:
United States Department of Defense | Defense Advanced Research Projects Agency (HR0011-18-2-0001)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93019C0007, 75N93019C00062, T32 AI 095202)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Center for Research Resources (1S10RR028106, UL1 RR024975-01, UL1 TR000445-06)
U.S. Department of Health & Human Services | NIH | National Center for Research Resources
U.S. Department of Health & Human Services | NIH | National Center for Research Resources
Merck KGaA | EMD Serono (2019 Future Insight Prize)
Vanderbilt University Medical Center (Dolly Parton COVID-19 Research Fund)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Helen Hay Whitney Foundation (Postdoctoral Fellowship)
- License Information
-
More Information
Article History
Received: 12 May 2020
Accepted: 26 June 2020
First Online: 10 July 2020
Competing interests
: R.S.B. has served as a consultant for Takeda and Sanofi Pasteur on issues related to vaccines. M.S.D. is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals and Eli Lilly, is on the scientific advisory board of Moderna and is a recipient of unrelated research grants from Moderna and Emergent BioSolutions. H.Y.C. has served as a consultant for Merck and GlaxoSmithKline and has received research funding from Sanofi Pasteur and research support from Cepheid, Genentech and Ellume. J.E.C. has served as a consultant for Sanofi and is on the scientific advisory boards of CompuVax and Meissa Vaccines, is a recipient of previous unrelated research grants from Moderna and Sanofi and is founder of IDBiologics. Vanderbilt University has applied for patents concerning SARS-CoV-2 antibodies that are related to this work. Emory University has applied for a patent concerning the plasmablast survival medium. S.P.J.W. and P.W.R. have filed a disclosure with Washington University for the recombinant VSV. J.E.D. and K.W.M. are employees of Berkeley Lights. All other authors declared no competing interests.
